
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics is a clinical-stage precision medicine company with a strong pipeline of candidates focused on targets in precision oncology and genetic disease. The company utilizes its unique Dynamo platform, which integrates advanced computational and experimental approaches, to design and develop new drugs that target previously intractable or inadequately addressed protein targets. The recent positive results from the clinical trials for its lead candidate, zovegalisib, demonstrate its potential to significantly improve upon existing treatments, while the broad potential of its technology opens up opportunities in multiple disease areas. With a solid financial position and a strong team, Relay Therapeutics is well-positioned for success in the long term.
Bears say
Relay Therapeutics is facing multiple challenges due to concerns over the impact of one of its drugs, Alpelisib, on pediatric growth. In addition, there may be limited room for further improvement and potential competition in the market, putting pressure on the stock. Furthermore, the company's reliance on future financing could lead to dilution for existing shareholders, creating financial risk.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares